FierceBiotech

@FierceBiotech

Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at

Washington, DC
Vrijeme pridruživanja: prosinac 2008.

Tweetovi

Blokirali ste korisnika/cu @FierceBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FierceBiotech

  1. Gilead publicly floated the idea of using remdesivir to treat the coronavirus, dubbed 2019-nCoV, 10 days ago. Since then, the effort to advance the drug in the indication has gathered pace.

    Poništi
  2. Craig Basson joins the early-stage private biotech after serving at the Swiss Big Pharma for a decade

    Poništi
  3. CEPI is supporting programs to develop coronavirus vaccines underway at groups including Inovio Pharmaceuticals and Moderna. The agreement with GSK positions CEPI to expand the support it can offer partner organizations

    Poništi
  4. 31. sij

    VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile.

    Poništi
  5. 31. sij
    Poništi
  6. 31. sij

    The bad news? These percentages drop for both women and people of color as you look up the ranks. Women make up 30% of executive teams and 18% of biotech company board members, while those numbers are 15% and 14% for people of color, respectively.

    Poništi
  7. 30. sij

    At the bottom of page 17 of its financial presentation, released as part of its full-year/Q4 results, are three experimental drugs stuck at the bottom of table with a big red arrow pointing down: Translation, they’ve been cut.

    Poništi
  8. 30. sij

    Ivarsson joins Moderna as it drives its hefty pipeline forward. One would think that with 21 programs, Moderna has its hands full. But it looks like the mRNA biotech is planning to build out its pipeline even more.

    Poništi
  9. 30. sij

    Details of the departure of the other NME to leave Roche’s pipeline in the fourth quarter emerged earlier this month when Chugai Pharmaceutical disclosed a licensing deal with Verastem Oncology.

    Poništi
  10. 30. sij

    Sanofi designed olipudase alfa, a recombinant human ASM, to stop that deterioration by ensuring patients have enough of the enzyme to gradually reduce levels of sphingomyelin. The results shared today validate that hypothesis.

    Poništi
  11. 29. sij

    The data are a mixed bag, with the primary endpoint success offset by the failure to improve secondary measures of relevance to the patient population.

    Poništi
  12. 29. sij

    The priority review applies to advanced RET fusion-positive NSCLC and two types of thyroid cancer.

    Poništi
  13. 28. sij

    He arrives at Philadelphia-based Century as the biotech nets a new chief technology officer: Greg Russotti, Ph.D., who wore various hats at Celgene, but was most recently vice president of cell therapy development and operations.

    Poništi
  14. 28. sij

    There’s a load of trials with its Merck-partnered Bavencio cancer drug that have been felled, but just two experimental trials: PF-06688992 in phase 1 for cancer and PF-04447943, also in phase 1 but for sickle cell anemia.

    Poništi
  15. 28. sij

    Earlier this month, Sorrento revealed it had received a buyout offer of up to $7 a share, a price that would translate into a deal worth upward of $1 billion.

    Poništi
  16. 28. sij

    Principia’s pipeline is built upon the idea of using BTK inhibitors to curb B-cell attacks against healthy tissues.

    Poništi
  17. 28. sij
    Poništi
  18. 27. sij

    Gasdermin D plays a role in multiple inflammatory cell death pathways; when those pathways are activated, the protein forms pores in the cell membrane.

    Poništi
  19. 17. sij
    Poništi
  20. 17. sij

    The tenth fund is significantly bigger than its predecessor, which topped out at $419 million in 2017. However, Dan Estes, general partner at Frazier, expects the additional funding to have little effect on the investment approach.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·